Viking Therapeutics Q2 Loss Widens to $128M; Cash $502M; Obesity Pipeline Advances
VKTX sits 46% above its 52-week low of $22.959.
Summary
Viking Therapeutics reported a wider Q2 2026 net loss of $128 million on surging R&D costs, while advancing its obesity pipeline with fully enrolled Phase 3 trials and upcoming data readouts.
Key Events · Earnings and Guidance · VKTX
-
Q2 Net Loss Widens to $128M
Net loss of $128.0 million ($1.10/share) vs $65.6 million ($0.58/share) in Q2 2025, driven by R&D expenses of $115.8 million (up from $60.2 million).
-
Cash Position Declines to $502M
Cash, equivalents, and short-term investments fell to $502 million at June 30, 2026, from $706 million at year-end 2025, reflecting heavy clinical trial spending.
-
Phase 3 VANQUISH Trials Fully Enrolled
Both VANQUISH-1 (~4,500 patients) and VANQUISH-2 (~1,000 patients) trials for subcutaneous VK2735 in obesity are fully enrolled and advancing.
-
Oral VK2735 Phase 3 Initiation Expected 4Q26
Company plans to start Phase 3 trials for oral VK2735 in obesity in the fourth quarter of 2026, positioning it as potentially the first oral dual GLP-1/GIP agonist.
Analysis · VKTX · Life Sciences
Viking's Q2 net loss more than doubled year-over-year to $128 million as R&D spending surged to $115.8 million, driven by the Phase 3 VANQUISH obesity program. The company ended the quarter with $502 million in cash, down from $706 million at year-end, providing runway but signaling accelerating cash burn. On the pipeline front, both VANQUISH trials are fully enrolled, oral VK2735 Phase 3 is on track for Q4 2026, and maintenance dosing data is due this quarter — milestones that could define the obesity franchise. The appointment of a new chief medical officer adds experienced leadership as the company scales toward potential commercialization.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VKTX was trading at $33.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $22.96 to $43.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.